Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Small molecule-induced mitochondrial disruption directs prostate cancer inhibition via UPR signaling.

Oncotarget | 2013

We previously identified SMIP004 (N-(4-butyl-2-methyl-phenyl) acetamide) as a novel inducer of cancer-cell selective apoptosis of human prostate cancer cells. SMIP004 decreased the levels of positive cell cycle regulators, upregulated cyclin-dependent kinase inhibitors, and resulted in G1 arrest, inhibition of colony formation in soft agar, and cell death. However, the mechanism of SMIP004-induced cancer cell selective apoptosis remained unknown. Here, we used chemical genomic and proteomic profiling to unravel a SMIP004-induced pro-apoptotic pathway, which initiates with disruption of mitochondrial respiration leading to oxidative stress. This, in turn, activates two pathways, one eliciting cell cycle arrest by rapidly targeting cyclin D1 for proteasomal degradation and driving the transcriptional downregulation of the androgen receptor, and a second pathway that activates pro-apoptotic signaling through MAPK activation downstream of the unfolded protein response (UPR). SMIP004 potently inhibits the growth of prostate and breast cancer xenografts in mice. Our data suggest that SMIP004, by inducing mitochondrial ROS formation, targets specific sensitivities of prostate cancer cells to redox and bioenergetic imbalances that can be exploited in cancer therapy.

Pubmed ID: 23902736 RIS Download

Research resources used in this publication

None found

Antibodies used in this publication

None found

Associated grants

  • Agency: NCI NIH HHS, United States
    Id: R01 CA125144
  • Agency: NIGMS NIH HHS, United States
    Id: R01 GM059780
  • Agency: NCI NIH HHS, United States
    Id: RC2 CA148414-02
  • Agency: NCI NIH HHS, United States
    Id: P20 CA132386-03
  • Agency: NCI NIH HHS, United States
    Id: P20 CA132386
  • Agency: NCI NIH HHS, United States
    Id: R01 CA167814
  • Agency: NIGMS NIH HHS, United States
    Id: P50 GM085764
  • Agency: NIGMS NIH HHS, United States
    Id: R01 GM59780
  • Agency: NCI NIH HHS, United States
    Id: R01 CA085679
  • Agency: NCI NIH HHS, United States
    Id: RC2 CA148414

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


ImageJ (tool)

RRID:SCR_003070

Open source Java based image processing software program designed for scientific multidimensional images. ImageJ has been transformed to ImageJ2 application to improve data engine to be sufficient to analyze modern datasets.

View all literature mentions

BioVision (tool)

RRID:SCR_005057

An Antibody supplier

View all literature mentions

MP Biomedicals (tool)

RRID:SCR_013308

An Antibody supplier

View all literature mentions

BIOMOL (tool)

RRID:SCR_013545

An Antibody supplier

View all literature mentions

IMR-90 (tool)

RRID:CVCL_0347

Cell line IMR-90 is a Finite cell line with a species of origin Homo sapiens

View all literature mentions

DU145 (tool)

RRID:CVCL_0105

Cell line DU145 is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions

LNCaP (tool)

RRID:CVCL_0395

Cell line LNCaP is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions

MDA-MB-231 (tool)

RRID:CVCL_0062

Cell line MDA-MB-231 is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions

Crl:NU(NCr)-Foxn1nu (tool)

RRID:IMSR_CRL:490

Mus musculus with name Crl:NU(NCr)-Foxn1nu from IMSR.

View all literature mentions